On July 1, 2022 KIT-AR, the augmented worker platform for the manufacturing industry, reported the completion of a €2m seed stage funding round (Press release, UCLB, JUL 1, 2022, View Source [SID1234616439]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This investment was co-led by Armilar Venture Partners and Caixa Capital Risc, with participation from RKKVC and Techtree fund (managed by Iberis Semper) and follow-on investment from Sintef Venture V and Best Horizon.

This round of financing will help KIT-AR push onwards with its goal to become the premier augmented worker platform for the manufacturing industry.

Incorporated in the United Kingdom, with a subsidiary in Portugal, KIT-AR has strong roots in applied research and innovation having spun out of UCL (University College London) and SINTEF, the largest research institute in Norway.

Marina Santilli, Associate Director of Physical Science and Engineering at UCLB, said: "Having followed the development of the team and the evolution of the product platform from its initial roots as a collaborative research project between UCL computer scientists and SINTEF engineers, I am delighted that KIT-AR has secured this significant seed funding award. I look forward to seeing the company evolve and grow even further."